AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04377711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Inhaler
Trial: NCT03378323
Drug: Multiple injection local anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple injection local anesthetic
Trial: NCT02792426
Drug: Nicorette Inhalator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00830206
Drug: Zithromax®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension
Trial: NCT03378323
Drug: Single injection local anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection local anesthetic
Trial: NCT00615472
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
Trial: NCT02715336
Drug: Ovulation induction with hCG and Lupron (GnRH agonist)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
Trial: NCT01019603
Drug: Tazaroc Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene gel applied daily for 22 days.
Trial: NCT03824119
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard postpartum care (including administration of NSAIDs)
Trial: NCT02096913
Drug: Dolormin® extra (Ibuprofen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period.
Trial: NCT03116659
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg PO BID x 14 days
Trial: NCT02607683
Drug: XAF5 (concentration A: 0.1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607683
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02867176
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
Trial: NCT02096913
Drug: Dolormin® extra (Ibuprofen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment.
Trial: NCT01276730
Drug: Interferon, Retinoic Acid and radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
Trial: NCT02211937
Drug: BI 44847 solution, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02211937
Drug: BI 44847 suspension, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02211937
Drug: BI 44847 tablet, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02211937
Drug: BI 44847 tablet, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00993070
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle gel, applied 4 times per day for 8 weeks
Trial: NCT01389102
Drug: Estradiol transdermal one 90 μL spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
Trial: NCT01389102
Drug: Estradiol transdermal spray, two 90 μL sprays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
Trial: NCT00133497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of saline placebo.
Trial: NCT00721305
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
Trial: NCT00002470
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01371162
Drug: RO5428029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT01371162
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses
Trial: NCT00978198
Drug: ASP1517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00978198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03610724
Drug: Bridging Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment phase could also include bridging therapy of investigator's choice
Trial: NCT04659421
Drug: combined therapy with rh-ES and CV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Trial: NCT01535859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily for 8 days.
Trial: NCT02549651
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
Trial: NCT03422419
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
Trial: NCT02549651
Drug: AZD9150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
Trial: NCT03136380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
Trial: NCT00742248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
Trial: NCT02536313
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Trial: NCT01470170
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
Trial: NCT04647877
Drug: phenytoin cream
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin cream to be applied on the neuropathic pain area
Trial: NCT04993040
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules
Trial: NCT02124278
Drug: PUL-042 Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01157754
Drug: levonorgestrel and ethynilestradiol
RxNorm normalized name: levonorgestrel and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04116528
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine or Placebo orally dissolving tablet
Trial: NCT02691572
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 15 µg will be administered in the subarachnoid space.
Trial: NCT02691572
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ketorolac 30 mg/8 h starting at the end of surgery.
Trial: NCT03420339
Drug: Stimulant
RxNorm normalized name: Stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The stimulants used must meet FDA dosage guidelines for age.
Trial: NCT00912002
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
Trial: NCT01020734
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04753710
Drug: Ocular gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation
Trial: NCT03625050
Drug: Usual care(Celecoxib and esomeprazole)
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
Trial: NCT02090413
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: enteric-coated capsule
Trial: NCT02090413
Drug: ASA-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT01045798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
Trial: NCT03594552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose placebo (oral tablet)
Trial: NCT01792804
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study drug 2
Trial: NCT04209543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet: administered orally once daily
Trial: NCT03514771
Drug: oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral isotretinoin
Trial: NCT02419937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection
Trial: NCT00004907
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02670824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT03697720
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take naproxen 500mg BID before and for the first 3 days of their period.
Trial: NCT04083846
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D744 Cap. 1 Cap., single oral administration under fed condition
Trial: NCT04083846
Drug: Test drug 1
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
Trial: NCT04083846
Drug: Test drug 2
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
Trial: NCT01199588
Drug: Nexagon® Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly, topical application of Nexagon® low dose used with compression dressings.
Trial: NCT02175238
Drug: BI 691751 after high fat breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose BI 691751 after a standardised high fat breakfast
Trial: NCT02914600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once a day
Trial: NCT00354198
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
Trial: NCT03717350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml of sodium chloride 0.9% within 15 minutes intravenously once
Trial: NCT00659321
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 weeks treatment with placebo
Trial: NCT02458469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo pill before bed-time
Trial: NCT02916290
Drug: Fuzhenghuayu
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01813006
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02171637
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalating doses
Trial: NCT01586611
Drug: 5FU, leucovorin, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
Trial: NCT03314298
Drug: testosterone anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous testosterone and anastrozole
Trial: NCT00004562
Drug: Platelet inhibitors
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive platelet inhibitors.
Trial: NCT00567762
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo eye drops
Trial: NCT02964260
Drug: Embolic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol/Gelatin sponge/PVA/Blank microspheres
Trial: NCT04321850
Drug: Zinc Sulfate 50 Mg Tab
RxNorm normalized name: zinc sulfate 50 MG
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The tablets were manufactured specifically for this study.
Trial: NCT04321850
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The tablets were manufactured specifically for this study.
Trial: NCT02469805
Drug: Choriomon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
Trial: NCT03527147
Drug: AZD5153
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5153 will be administered orally once per day (qd).
Trial: NCT02967159
Drug: AZD7594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: AZD7594 440 μg via DPI
Trial: NCT00861120
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 on day 1 of a 28 days cycle
Trial: NCT00393029
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
Trial: NCT00909402
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
Trial: NCT02023606
Drug: SPN-810M
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04737408
Drug: Rosuvastatin 40mg
RxNorm normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40 mg
Trial: NCT02100228
Drug: Parenteral heparin and/or oral Vitamin K antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
Trial: NCT02024932
Drug: BVS857
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Trial: NCT02024932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Trial: NCT02320669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of Placebo followed by infusion for 48 hours
Trial: NCT04611789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT02235662
Drug: TFV IVR
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03707912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT04380337
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
Trial: NCT04380337
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
Trial: NCT04380337
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
Trial: NCT03547583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and sham up-titration at weeks 2, 4, and 6
Trial: NCT00172133
Drug: ALX1-11 (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
Trial: NCT03348423
Drug: DEX-IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN Dexmedetomidine + IV placebo
Trial: NCT03348423
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IN Placebo + IV Fentanyl
Trial: NCT03348423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN Placebo + IV Placebo
Trial: NCT02817841
Drug: 15 mg E4/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Trial: NCT03952559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03952559
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as standard-of-care
Trial: NCT01860105
Drug: MDCO-157
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT00003114
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
Trial: NCT03744364
Drug: Dinoprostone 10mg
RxNorm normalized name: DINOPROSTONE 10MG INSERT,VAG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.